PITTSBURGH, July 17, 2014 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced that the U.S. District Court for the
District of New Jersey granted its
motion for a permanent injunction against GlaxoSmithKline (GSK) in
relation to Paroxetine CR, the generic version of GSK's
Paxil® CR. GSK is now precluded from supplying product
to Apotex, which marketed the product as an authorized generic.
Mylan had previously been awarded damages in the amount of
$106,700,000 by the District Court
after a favorable jury verdict in March 2014.
In addition, the District Court awarded Mylan prejudgment
interest and permitted it to take an accounting so that Mylan can
determine the amount of additional damages it has suffered since
Sept. 30, 2013 as a result of GSK's
ongoing breach. All of GSK's post-trial motions were denied.
Mylan is the only company to have successfully developed an
FDA-approved generic version of this product.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for
it. See for yourself. See inside. mylan.com
Logo - http://photos.prnewswire.com/prnh/20140423/77793
SOURCE Mylan Inc.